title: Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
abstract: Chronic hepatitis C (CH-C) genotype 1 patients who achieved early virologic response have a high probability of sustained virologic response (SVR) following pegylated interferon (Peg-IFN) plus ribavirin therapy. This study was conducted to evaluate how reducing drug doses affects complete early virologic response (c-EVR) defined as hepatitis C virus (HCV) RNA negativity at week 12. Nine hundred eighty-four patients with CH-C genotype 1 were enrolled. Drug doses were evaluated independently on a body weight base from doses actually taken. From multivariate analysis, the mean dose of Peg-IFN alpha-2b during the first 12 weeks was the independent factor for c-EVR (P = 0.02), not ribavirin. The c-EVR rate was 55% in patients receiving > or = 1.2 microg/kg/week of Peg-IFN, and declined to 38% at 0.9-1.2 microg/kg/week, and 22% in patients given <0.9 microg/kg/week (P < 0.0001). Even with stratified analysis according to ribavirin dose, the dose-dependent effect of Peg-IFN on c-EVR was observed, and similar c-EVR rates were obtained if the dose categories of Peg-IFN were the same. Furthermore, the mean dose of Peg-IFN during the first 12 weeks affected HCV RNA negativity at week 24 (P < 0.0001) and SVR (P < 0.0001) in a dose-dependent manner. Our results suggest that Peg-IFN was dose-dependently correlated with c-EVR, independently of ribavirin dose. Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1.
authors: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 565-0871, Japan.
authors: T
authors: T
authors: Oze
authors: N
authors: N
authors: Hiramatsu
authors: T
authors: T
authors: Yakushijin
authors: M
authors: M
authors: Kurokawa
authors: T
authors: T
authors: Igura
authors: K
authors: K
authors: Mochizuki
authors: K
authors: K
authors: Imanaka
authors: A
authors: A
authors: Yamada
authors: M
authors: M
authors: Oshita
authors: H
authors: H
authors: Hagiwara
authors: E
authors: E
authors: Mita
authors: T
authors: T
authors: Ito
authors: Y
authors: Y
authors: Inui
authors: T
authors: T
authors: Hijioka
authors: S
authors: S
authors: Tamura
authors: H
authors: H
authors: Yoshihara
authors: E
authors: E
authors: Hayashi
authors: A
authors: A
authors: Inoue
authors: Y
authors: Y
authors: Imai
authors: M
authors: M
authors: Kato
authors: Y
authors: Y
authors: Yoshida
authors: T
authors: T
authors: Tatsumi
authors: K
authors: K
authors: Ohkawa
authors: S
authors: S
authors: Kiso
authors: T
authors: T
authors: Kanto
authors: A
authors: A
authors: Kasahara
authors: T
authors: T
authors: Takehara
authors: N
authors: N
authors: Hayashi
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b